CGON Stock Forecast & Price Target

CG Oncology Inc. is positioned for significant financial growth with projections indicating launch sales of approximately $2.6 billion by 2034, driven by the premium pricing strategy for its immunotherapy candidate, cretostimogene grenadenorepvec. The company is well-prepared for commercialization, with estimations of regulatory approval and market launch by late 2026, which is reinforced by strong management confidence in their manufacturing and commercial readiness. Furthermore, the potential expansion of creto into additional patient populations and evidence of differentiated efficacy and durability strengthens the market outlook, suggesting a promising trajectory for revenue growth in the bladder cancer treatment landscape.

CG Oncology's stock outlook is negatively impacted by the potential for disappointing trial results and delays in regulatory submissions, which could hinder the company's ability to commercialize its bladder cancer treatment. Additionally, the risks associated with reimbursement challenges in the face of competitor advantages and potential lapses in intellectual property could undermine its market position and investor confidence. Lastly, market reactions to negative clinical outcomes could lead to significant declines in stock value, as indicated by a projected 30% probability of such scenarios occurring.